Barclays analyst Andrew Mok lowered the firm’s price target on DaVita (DVA) to $149 from $160 and keeps an Equal Weight rating on the shares as part of a Q3 earnings preview for the health care facilities and managed care group. The firm continues to think Medicare is the most stable, Medicaid the most uncertain, and the Affordable Care Act exchanges are inflecting positively from both a fundamental and policy perspective.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVA:
- Private Markets: Databricks valued at over $100B in latest fundraising
- DaVita price target lowered to $140 from $145 at BofA
- DaVita Announces Strategic Initiative for Operational Efficiency
- DaVita increases existing share repurchase authorization by $2B
- Berkshire trimmed Apple, DaVita, Charter, Bank of America stakes in Q2